Key clinical point: Overall survival of patients with treatment-naive advanced lung cancer was better with osimertinib than with comparator TKIs.
Major finding: Median OS was 38.6 months with osimertinib vs. 31.8 months with comparator TKIs.
Study details: Randomized phase 3 clinical trial in 556 patients with EGFR-mutant NSCLC.
Disclosures: FLAURA was sponsored by AstraZeneca. Dr. Ramalingam disclosed honoraria, an advisory or consulting role, and research funding from that company and others. Dr. Garrido disclosed a speaker and advisory role for AstraZeneca and others.
Ramalingam S et al. ESMO 2019. Abstract LBA5_PR.